When clinical programs fail, the default assumption is science. The molecule did not work. The patient population was wrong. The design was flawed. But failure is rarely caused by science alone. It happens in the gaps between intent, decision, and execution. A vendor does not understand the requirement and builds the wrong thing. A handoff between teams loses critical context. An assumption about feasibility or timeline was never tested. Leadership makes a decision based on incomplete information and nobody says so. Accountability for execution failure is unclear, so the failure gets attributed to science. If we misdiagnose execution failure as scientific failure, we repeat the pattern. We optimize the wrong thing. We change the protocol instead of the execution system. We blame the science when the problem is in the delivery.
Key Takeaways
Key Takeaways
- Most clinical failures attributed to science actually originate in execution gaps: unclear requirements, poor handoffs, unexamined assumptions, or missing accountability for decisions.
- Execution failure happens at the intersection of intent (what we said we would do), decision (what we committed to), and delivery (what actually happened).
- Kieran Engels and Seuss+ help biotech teams distinguish execution failure from scientific failure by building clarity into governance before programs launch.
- Misdiagnosing execution failure as scientific failure leads teams to optimize the wrong variables and repeat the same execution patterns.
- Distinguishing failure types requires clarity in documentation: decision rationale, assumptions tested, accountability assigned, and execution criteria defined.
The Default Attribution Problem
When something fails in a clinical program, the first place people look is science. Did the drug work? Was the population right? Was the endpoint sensitive? These are important questions, but they are not the only questions.
The problem is that execution failure and scientific failure look similar from the outside. Both result in a program that does not work. But they require different solutions. If you misdiagnose, you will solve for the wrong problem and repeat the failure.
Where Execution Failure Lives
Execution failure happens in three places. Between intent and decision: leadership decides on a timeline without asking if vendors can deliver it. Between decision and delivery: a vendor understands the requirement differently than leadership intended. In delivery itself: unclear accountability means nobody catches the drift.
These failures are not bugs. They are features of systems that do not have clear governance.
Scientific Failure vs. Execution Failure
| Dimension | Scientific Failure | Execution Failure | How to Distinguish |
| Root Cause | Drug or biology did not work as expected | Unclear requirement, poor handoff, missing accountability | Review decision documentation and assumption testing |
| Indicators | Data shows lack of efficacy or safety signal | Delivery does not match what was promised or agreed | Check vendor communication, requirement clarity, handoff records |
| Solution Path | Protocol refinement, patient population adjustment | Governance improvement, clarity in requirements, accountability assignment | Trace execution gaps during post-mortem |
Building Systems to Prevent Misdiagnosis
The fix is not process. The fix is clarity. Before a program launches, document the intent. What are we trying to prove? What assumptions are we making? What happens if those assumptions break? Who is responsible for each decision? What are vendors committing to?
This documentation serves two purposes. First, it prevents execution failure by making intent explicit. Second, if failure happens anyway, it provides the diagnostic framework to distinguish execution failure from scientific failure.
Kieran Engels and Seuss+ work with biotech teams to build this diagnostic clarity through vendor governance and execution planning. Learn more at seuss.plus/about-us/.
If we misdiagnose execution failure as scientific failure, we repeat the pattern. We optimize the wrong thing. We change the protocol instead of the execution system."
Key Industry Data
FDA issued 303 warning letters in FY2025, a 59% increase from FY2024, with 135 directly based on inspection findings. (Source: FDA)
The most frequently cited inspection findings involve safety documentation delays, sponsor failure to monitor, and failure to select qualified monitors. (Source: EMA/FDA analysis)
Responses to Form 483 observations must be submitted within 15 business days. (Source: FDA)
The FDA issues Establishment Inspection Reports within 45 days of completing an inspection, and these become publicly available 3 to 6 months after the conclusion. (Source: FDA)
Inspection readiness planning should begin 6 to 12 months before regulatory submission to ensure all systems, documentation, and personnel are audit ready. (Source: Regulatory affairs guidance)
Frequently Asked Questions
Look for patterns in the documentation trail. Is the requirement clear in writing? Did the vendor sign off on feasibility? Are handoffs documented? If the documentation is vague or missing, execution failure is likely. If the documentation is clear and was followed, the failure is more likely scientific.
Yes. A program can fail because the science does not work and because the trial was not executed properly. But you have to distinguish between them to learn from the failure correctly.
High. You change the protocol instead of fixing the execution system. You repeat the same governance failures on the next program. You lose the learning you should have gained.
Absolutely. Documented assumptions serve two purposes. They prevent execution failure by making implicit thinking explicit. They enable accurate diagnosis if failure happens anyway.
By embedding clarity into decision-making. Clear requirements mean vendors understand what they are building. Clear accountability means someone is responsible for catching drift. Clear assumptions mean teams test what matters before committing to execution.
About the Author
Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.
